Thursday November 26 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

CureVac GmbH

We are dedicated to offering reliable and innovative RNA related products and services to the Life Science Community. siRNA [order here]: ultrapure (HPLC purified)
For the design of siRNA please use EMBOSS.


Oligonucleotides [order here]: Customized small and large scale production, modifications, and labelling (HPLC purified)


RNActive™ [info] stabilized mRNA for enhanced gene expression:
Custom tailored RNActive™ purified by our proprietary chromatography technology PUREmessenger™


Contact Details:
Paul-Ehrlich-Str. 15
Tübingen
72076
Germany
Tel:49 - 70 71 - 9 20 53 - 0
Fax:49 - 70 71 - 9 20 53 - 11
Email:
WWW:

www.curevac.com/




Recent Publications by CureVac GmbH:

Vaccination with messenger RNA.
As an alternative to DNA-based vaccines, messenger RNA (mRNA)-based...
13th October, 2006
CureVac GmbH, Tubingen, Germany. Methods Mol Med. 2006;127:23-40.
DOI Direct Link
Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro.
The efficiency of test vaccines needs to be evaluated by quantification of...
30th August, 2005
CureVac GmbH, Paul-Ehrlich-Str. 15, 72076, Tubingen, Germany. Cell Mol Life Sci. 2005 Aug;62(15):1755-62.
DOI Direct Link
Messenger RNA-based vaccines.
RNA is the only molecule known to recapitulate all biochemical functions...
19th July, 2005
CureVac GmbH, Paul Ehrlich Strasse 15, 72076 Tubingen, Germany. Expert Opin Biol Ther. 2004 Aug;4(8):1285-94.
DOI Direct Link
Co-transfection of messenger RNA and siRNA as a method to study the efficiency of siRNA.
The definition of an optimal siRNA results from the in vitro testing of...
8th July, 2005
CureVac GmbH, Tubingen, Germany. Nucleosides Nucleotides Nucleic Acids. 2005;24(2):147-52.
Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA.
We reported that RNA condensed on protamine is protected from...
29th June, 2005
CureVac GmbH, Tubingen, Germany. Eur J Immunol. 2005 May;35(5):1557-66.
DOI Direct Link

View more CureVac GmbH research publications.

BioNews Results for CureVac GmbH:

CureVac GmbH (DE) - CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer
Pharma Live:  Nov 3 2009 1:41AM Matching: curevac gmbh
CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer
HUGIN Online:  Nov 2 2009 8:25AM Matching: curevac gmbh
CureVac launches Phase IIa mRNA Vaccine Trial in Prostate Cancer
PR inside:  Nov 2 2009 7:50AM Matching: curevac gmbh

CureVac GmbH Clinical Trials:

Trial of an RNActive®-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 352 times since April 2007, the link to the organisation's website has been followed 67 times

Recent Search Terms used to find this page: RNA protamin protected | curevac | Curevac publications | .

Search for more companies in Tübingen

Search for more companies in



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for CureVac GmbH

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.